AstraZeneca's Ultomiris reduces urine protein in late-stage trial of rare kidney disease

AstraZeneca said Ultomiris met the main goal of a late-stage trial, reducing protein found in the urine of patients with a rare kidney disease. The result is a positive clinical-development update for the drug and supports its broader therapeutic profile. The news is likely supportive for AstraZeneca shares but is not by itself a major market-moving catalyst.

Analysis

AstraZeneca said Ultomiris met the main goal of a late-stage trial, reducing protein found in the urine of patients with a rare kidney disease. The result is a positive clinical-development update for the drug and supports its broader therapeutic profile. The news is likely supportive for AstraZeneca shares but is not by itself a major market-moving catalyst.